| Autor: |
Rosenmann, Hanna, Meiner, Zeev, Kahana, Esther, Aladjem, Zoja, Friedman, Gideon, Ben‐Yehuda, Arie, Grenader, Tal, Wertman, Eli, Abramsky, Oded |
| Zdroj: |
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics; July 2004, Vol. 128 Issue: 1 p123-125, 3p |
| Abstrakt: |
Accumulating evidence indicates that the heparan‐sulfate‐proteoglycan (perlecan, HSPG2), as well as other specific proteoglycans, are involved in amyloidogenesis and tau aggregation in Alzheimer's disease (AD). Moreover, the HSPG2 is located on chromosome 1p36, a region of linkage to late‐onset AD (LOAD). These two criteria, pathological and positional, make the HSPG2 an interesting candidate for an association with AD. We performed a case‐control association study between the common intron 6 BamHI polymorphism at a region of putative heparan‐sulfate (HS) attachment sites in the HSPG2 gene and sporadic AD in Jews. No association was detected with AD, neither as a risk factor nor as a modifier gene affecting the age at disease onset and disease progression. In addition, no interactive effect was found with the known risk factor for AD, the apolipoprotein E (APOE) ɛ4. These findings show no evidence for association between HSPG2 intron 6 BamHI polymorphism and AD in our population. © 2004 Wiley‐Liss, Inc. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text